Developer scraps treatment for 2 MD types after disappointing trial results
Oral drug for Becker, Duchenne failed to offer benefits vs. a placebo
Written by |
Development of sevasemten for BMD and DMD is being stopped due to a lack of effectiveness, Servier announced in a letter to the MD community. (Image from iStock)
Drug maker Servier announced that it is discontinuing development of its oral treatment candidate sevasemten for both Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD).
The announcement comes just days after top-line data, or the first results of a clinical trial, showed that sevasemten had failed to hit the main goal or key secondary goals in a global study dubbed GRAND CANYON (NCT05291091). The Phase 2 trial had tested the med versus a placebo in 175 men and boys with DMD, the most common type of muscular dystrophy.
In a letter to the community, Servier said that a governance committee review of data from GRAND CANYON confirmed that sevasemten appeared to offer no benefit relative to the placebo. The company noted that no new safety issues were reported with the drug’s use.
Similar reviews of data from a pair of Phase 2 trials in DMD — LYNX (NCT05540860) and FOX (NCT06100887) — also found insufficient evidence to support continued development of sevasemten for the treatment of Duchenne. As such, Servier informed community members that it’s pulling the plug on the sevasemten program for both diseases.
“We have made the difficult decision to stop the research studies for sevasemten for both Becker and Duchenne muscular dystrophy. We know that this news is deeply disappointing for both communities and recognize the hope that people have placed in sevasemten as a potential treatment option for Becker and Duchenne,” states Servier’s letter, which is signed by three members of the company’s patient advocacy team, who used first names only.
No timeline was given for future action, but the letter said that the company “[plans] to hold webinars soon” to engage with community members.
The letter emphasizes that even though sevasemten showed no benefit, negative results can still be useful for understanding disease biology, thus providing a better foundation for future research.
“While these results were not what we had hoped for, there is still much to learn from these studies. Our teams will continue to conduct an in-depth analysis of the data to better understand the results,” the letter states. It adds: “We are committed to sharing what we learn with the Becker and Duchenne communities, as well as the broader scientific community, so that this knowledge can help inform and advance future research.”
Developer thanks all those taking part in sevasemten trials
The letter also offers gratitude to all the participants — and their families — who took part in clinical trials of sevasemten.
“We recognize the time, effort, and trust that participation in clinical research requires, and we are deeply grateful to every participant, caregiver, investigator, and clinical team who made this work possible. Your contributions are meaningful, and the knowledge gained through this research will remain an important part of our collective understanding of Becker and Duchenne,” the letter states.
Servier said it will provide additional updates as soon as more information becomes available. The company also affirmed its commitment to supporting the BMD and DMD communities going forward. In the meantime, individuals who have participated in sevasemten trials are encouraged to get in touch with their care team to discuss next steps for their specific situation.
“We understand that this news brings uncertainty and may raise questions about what comes next. While we do not have all the answers today, we will continue to engage with the community as we learn more,” the letter concludes. “Thank you for the trust you have placed in us, for the perspectives you have shared, and for allowing us to be part of this community.”
2 patient advocacy groups call decision ‘deeply disappointing’
BMD and DMD are both genetic disorders marked by a deficiency of dystrophin, a protein that normally acts like a shock absorber in muscle cells. Lacking dystrophin, muscles accumulate excessive wear and tear and damage over time, ultimately driving progressive muscle weakness and other disease symptoms.
Sevasemten had been designed to block a protein called myosin, which plays a key role in muscle contractions. It was hoped that the treatment might help make muscle contractions more gently, thus reducing damage and ultimately slowing disease progression. Servier acquired rights to the experimental medication from Edgewise Therapeutics earlier this year.
In a statement, the advocacy organization Parent Project Muscular Dystrophy said news of sevasemten’s discontinuation is “deeply disappointing for the Duchenne and Becker communities.” According to the nonprofit, it “represents another significant setback for individuals and families who had been following this research and hoping it might lead to a new therapeutic option.”
The Muscular Dystrophy Association echoed the same sentiment in its own statement: “We recognize that this news is deeply disappointing for people and families living with BMD and DMD, particularly those who participated in the LYNX and FOX and GRAND CANYON clinical trials or were hopeful that sevasemten might become another treatment option.” The statement noted that “these outcomes are not what the community had hoped for.”
Leave a comment
Fill in the required fields to post. Your email address will not be published.